Drug intelligence / Profile preview

TenoBoost

Development stage: Preclinical
Lead developer: Peaches Biotech
Modality: Recombinant Proteins and Enzymes
Administration: Intralesional

Overview

TenoBoost (also known as PRS TenoBoost) is an allogeneic biological product under development by Peaches Biotech for tendon regeneration and the treatment of tendinosis. Developed under the company's patented PRS® (Selective Rich Plasma) technology, TenoBoost is a tissue-specific secretome (cytokine and growth factor concentrate) obtained by co-culturing M2-type macrophages with primary tenocytes. This co-culture process induces cellular immunomodulation and stimulates the release of selective growth factors tailored specifically for tendon tissue regeneration. TenoBoost is designed to accelerate physiological recovery from tendon injuries, optimize tissue regeneration, and prevent fibrosis, offering a targeted alternative to traditional platelet-rich plasma (PRP) therapies.

Other names: PRS TenoBoost

Beyond the preview

Go deeper on TenoBoost.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TenoBoost.